spacer gif spacer gif spacer gif spacer gif spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vojtesek, B.
Right arrow Articles by Lane, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vojtesek, B.
Right arrow Articles by Lane, D. P.
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V. and Vogelstein, B (1990). Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912-915.[Abstract/Free Full Text]

Barnes, D. M., Hanby, A. M., Gillett, C. E., Mohommed, S., Hodgson, S., Bobrow, L. G., Leigh, I. M., Purkis, T., MacGeoch, C., Spurr, N. K.,612Bartek, J., Vojte\377s\377ek, B., Picksley, S. M. and Lane, D. P (1992). Abnormal expression of wild type p53 in normal cells of a cancer family patient. Lancet 340, 259-263.[Medline]

Bartek, J., Bartkova, J., Vojte\377s\377ek, B., Staskova, Z., Lukas, J., Rejthar, A., Kovarik, J., Midgley, C. A., Gannon, J. V. and Lane D. P (1991). Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6, 1699-1703.[Medline]

Bartek, J., Bartkova, J., Vojte\377s\377ek, B., Staskova, Z., Rejthar, A., Kovarik, J. and Lane, D. P (1990). Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro. Int. J. Cancer 46, 839-844.[Medline]

Bartek, J., Iggo, R., Gannon, J. and Lane, D. P (1990). Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5, 893-899.[Medline]

Bennett, W. P., Hollstein, M. C., He, A., Zhu, S. M., Resau, J., Trump, B. F., Metcalf, R. A., Welsh, J. A., Gannon, J. V., Lane, D. P. and Harris, C. C (1991). Archival analysis of p53 genetic and protein alterations in chinese esophageal cancer. Oncogene 6, 1779-1784.[Medline]

Casey, G., Lohsueh, M., Lopez, M. E., Vogelstein, B. and Stanbridge, E. J (1991). Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6, 1791-1997.[Medline]

Cattoretti, G., Rilke, F., Andreola, S., D'Amato, L. and Delia, D (1988). p53 expression in breast cancer. Int. J. Cancer 41, 178-183.[Medline]

Chen, P.-L., Chen, Y., Bookstein, R. and Lee, W.-H (1990). Genetic mechanism of tumor suppression by the human p53 gene. Science 250, 1576-1580.[Abstract/Free Full Text]

Crawford, L. V., Pim, D. C. and Lamb, P (1984). The cellular protein p53 in human tumors. Mol. Biol. Med 2, 261-272.[Medline]

Davidoff, A. M., Humphrey, P. A., Igelhart, J. D. and Marks, J. R (1991). Genetic basis for p53 overexpression in human breast cancer. Proc. Nat. Acad. Sci. USA 88, 5006-5010.[Abstract/Free Full Text]

Deppert, W. and Steinmayer, T (1989). Metabolic stabilisation of p53 in SV40 transformed cells correlates with the expression of the transformed phenotype but is independent from complex formation. Curr. Top. Microbiol. Immunol 144, 77-83.[Medline]

Deppert, W., Steinmayer, T. and Richter, W (1989). Cooperation of SV40 large T antigen and the cellular protein p53 in maintainence of cell transformation. Oncogene 4, 1103-1110.[Medline]

Gannon, J. V., Greaves, R., Iggo, R. and Lane, D. P (1990). Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9, 1595-1602.[Medline]

Gannon, J. V. and Lane, D. P (1991). Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. Nature 349, 802-806.[Medline]

Ginsberg, D., Michael-Michalovitz, D., Ginsberg, D. and Oren, M (1991). Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localisation and decreased stability of the protein. Mol. Cell. Biol 11, 582-585.[Abstract/Free Full Text]

Goyette, M. C., Cho, K., Fasching, C. L., Levy, D. B., Kinzler, K. W., Paraskeva, C., Vogelstein, B. and Stanbridge, E. J (1992). Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol. Cell. Biol 12, 1387-1395.[Abstract/Free Full Text]

Hall, P. A., McKee, P. H., Menage, H. D., Dover, R. and Lane, D. P (1993). High levels of p53 protein in UV irradiated human skin. Oncogene 8, 203-207.[Medline]

Hanahan, D., Lane, D. P., Lipsich, L., Wigler, M. and Bothan, M (1980). Characterisation of an SV40-plasmid recombinant and its movement into and out of the genome of a murine cell. Cell 21, 127-139.[Medline]

Harlow, E., Crawford, L. V., Pim, D. C. and Williamson, N. M (1981). Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol 39, 861-869.[Abstract/Free Full Text]

Hartwell, L (1992). Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 71, 543-546.[Medline]

Iggo, R., Gatter, K., Bartek, J., Lane, D. and Harris, A. L (1990). Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335, 675-679.[Medline]

Kastan, M. B., Zhan, Q., El-Deiry, W. K., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B. and Fornace, A. J (1992). A mammalian cell cycle checkpoint pathway utilising p53 and gadd45 is defective in Ataxia-Telangiectasia. Cell 71, 587-597.[Medline]

Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V. and Kastan, M. B (1992). Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Nat. Acad. Sci.USA 89, 7491-7495.[Abstract/Free Full Text]

Lane, D. P (1992). p53, guardian of the genome. Nature 358, 15-16.[Medline]

Lu, X., Park, S. H., Thompson, T. C. and Lane, D. P (1992). ras -induced hyperplasia occurs with mutation of p53, but an activated ras and myc together can induce carcinoma without p53 mutation. Cell 70, 153-161.[Medline]

Maltzman, W. and Czyzyk, L (1984). UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol 4, 1689-1694.[Abstract/Free Full Text]

Martin, H. M., Filipe, M. I., Morris, R. W., Lane, D. P. and Silvestre, F (1992). p53 expression and prognosis in gastric carcinoma. Int. J. Cancer 50, 859-862.[Medline]

Martinez, J., Georgoff, I., Martinez, J. and Levine, A. J (1991). Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev 5, 151-159.[Abstract/Free Full Text]

Mercer, W. E., Amim, M., Sauve, G. J., Appella, E., Ullrich, S. J. and Romano, J. W (1990). Wild type human p53 is antiproliferative in SV40-transformed hamster cells. Oncogene 5, 973-980.[Medline]

Mercer, W. E., Shields, M. T., Lin, D., Appella, E. and Ullrich, S. J (1991). Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc. Nat. Acad. Sci. USA 88, 1958-1962.[Abstract/Free Full Text]

Michalovitz, D., Halvey, O. and Oren, M (1990). Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62, 671-680.[Medline]

Midgley, C. A., Fisher, C. J., Bartek, J., Vojte\377s\377ek, B., Lane, D. P. and Barnes, D. M (1992). Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in E. coli. J. Cell. Sci 101, 183-189.[Abstract/Free Full Text]

Momand, J., Zambetti, G. P., Olson, D. C., George, D. and Levine, A. J (1992). The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245.[Medline]

Oren, M., Maltzman, W. and Levine, A. J (1981). Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol. Cell. Biol 1, 101-110.[Abstract/Free Full Text]

Reihsaus, E., Kohler, M., Kraiss, S., Oren, M. and Montenarh, M (1990). Regulation of the level of the oncoprotein p53 in non-transformed and transformed cells. Oncogene 5, 137-145.[Medline]

Rodrigues, N. R., Rowan, A., Smith, M. E. F., Kerr, I. B., Bodmer, W. F., Gannon, J. and Lane, D. P (1990). p53 mutations in colorectal cancer. Proc. Nat. Acad. Sci. USA 87, 7555-7559.[Abstract/Free Full Text]

Sarnow, P., Ho, Y. S., Williams, J. and Levine, A. J (1982). Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54Kd cellular protein in transformed cells. Cell 28, 387-394.[Medline]

Simanis, V. and Lane, D. P (1985). An immunoaffinity purification procedure for SV40 large T antigen. Virology 144, 88-100.[Medline]

Srivastava, S., Zou, Z., Pirollo, K., Blattner, W. and Chang, E. H (1990). Germ-line transmission of a mutated p53 gene in a cancer prone family with Li-Fraumeni syndrome. Nature 348, 747-749.[Medline]

Thor, A. D., Moore, D. H., Edgerton, S. M., Kawasaki, E. S., Reihsaus, E., Lynch, H. T., Marcus, J. N., Schwartz, L., Chen, L.-C., Mayall, B. H. and Smith, H. S (1992). Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Nat. Cancer Inst 84, 845-855.[Abstract/Free Full Text]

Yewdell, J. W., Gannon, J. V. and Lane, D. P (1986). Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol 59, 444-452.[Abstract/Free Full Text]


This article has been cited by other articles:


Home page
 Cancer Res.Home page
T. R. Singh, S. Shankar, X. Chen, M. Asim, and R. K. Srivastava
Synergistic Interactions of Chemotherapeutic Drugs and Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo-2 Ligand on Apoptosis and on Regression of Breast Carcinoma in Vivo
Cancer Res., September 1, 2003; 63(17): 5390 - 5400.
[Abstract] [Full Text] [PDF]

Home page
 Vet PatholHome page
P. R. Nambiar, M. L. Jackson, J. A. Ellis, B. J. Chelack, B. A. Kidney, and D. M. Haines
Immunohistochemical Detection of Tumor Suppressor Gene p53 Protein in Feline Injection Site-associated Sarcomas
Vet. Pathol., March 1, 2001; 38(2): 236 - 238.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
K.-W. Chang, S. Sarraj, S.-C. Lin, P.-I Tsai, and D. Solt
p53 expression, p53 and Ha-ras mutation and telomerase activation during nitrosamine-mediated hamster pouch carcinogenesis
Carcinogenesis, July 1, 2000; 21(7): 1441 - 1451.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. M. Keane, S. A. Ettenberg, M. M. Nau, E. K. Russell, and S. Lipkowitz
Chemotherapy Augments TRAIL-induced Apoptosis in Breast Cell Lines
Cancer Res., February 1, 1999; 59(3): 734 - 741.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Sepp-Lorenzino and N. Rosen
A Farnesyl-Protein Transferase Inhibitor Induces p21 Expression and G1 Block in p53 Wild Type Tumor Cells
J. Biol. Chem., August 7, 1998; 273(32): 20243 - 20251.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Summary Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vojtesek, B.
Right arrow Articles by Lane, D. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vojtesek, B.
Right arrow Articles by Lane, D. P.